Bcr-Abl is a constitutively active tyrosine kinase involved in the development and progression of chronic myeloid leukaemia (CML). It has been demonstrated that Bcr-Abl-positive cells can be uniquely resistant to apoptosis induced by different types of stimuli, but the mechanism by which this is achieved is not defined. In this study we have investigated how cells expressing high expression levels of Bcr-Abl may gain resistance to cytotoxic drugs. We have established cell lines expressing low and high expression levels of Bcr-Abl. Cells expressing elevated Bcr-Abl are resistant to cytotoxic drugs. In drug-sensitive 32D-parental and low Bcr-Abl expressing cells, pro-apoptotic Bcl-2 family members, Bax and Bad translocate from the cytosol to the mitochondrion following a cytotoxic insult. In contrast, high Bcr-Abl expression prevents the early translocation of these pro-apoptotic proteins to the mitochondrion, mitochondrial membrane potential is retained and caspases are inactive. We also demonstrate that IL-3 can contribute to drug resistance in low Bcr-Abl expressing cells, however, independent inhibition of IL-3 activated pathways (PI3K/AKT and Jak/STAT) does not sensitise cells to apoptosis. This study demonstrates that the subcellular translocation of Bax and Bad can be regulated by elevated Bcr-Abl expression and this may be a key event in the abrogation of an apoptotic response following a cytotoxic insult.
Introduction
Blast crisis phase chronic myeloid leukaemia (CML) cells generally exhibit resistance to apoptosis induced by chemotherapeutic drugs. The expression of the Bcr-Abl onco-protein is the hallmark of CML, and expression is frequently elevated at blast crisis. We have previously shown that high expression levels of Bcr-Abl are sufficient to achieve drug resistance. 1 However, the primary mechanisms that enable cytotoxic drug resistance in these cells are undefined. The Bcl-2 family members have been implicated in Bcr-Abl-mediated resistance to apoptosis induced by cytokine withdrawal and cytotoxic agents. 2, 3 Also, a specific inhibitor of Bcr-Abl kinase activity, STI571, has been reported to induce apoptosis in Bcr-Ablpositive cells by the down-regulation of the anti-apoptotic BclxL protein.
Importantly, the activation of STAT5 has been shown to be essential for transformation by Bcr-Abl. 9, 10 Maximal Bcl-xL expression requires the activation of STAT5 in response to BcrAbl. 11 Although Jak activation has not been consistently detected in Bcr-Abl-positive cells, it is still unclear whether activation of STATs by Bcr-Abl is Jak dependent or whether Jak2 activation is required for resistance to drug-induced apoptosis.
The PI3K/AKT pathway also plays a role in the antiapoptotic function of IL-3 and the transforming activity of BcrAbl. 12 However, activation of PI3K by IL-3 alone cannot protect against DNA damage-induced apoptosis. 13 A cooperation between STAT5 and PI3K in the suppression of IL-3 withdrawal-induced apoptosis has been documented. 14 To investigate the role of these pathways in Bcr-Abl-mediated drug resistance we employed the kinase inhibitors AG490 and LY294002, to inhibit the activities of Jak2 and PI3K, respectively.
A large number of Bcl-2 family members has been identified, all of which possess one or more Bcl-2 homology domains (BH domains), and the family can be subdivided into pro-and anti-apoptotic members. The pro-apoptotic members include Bax, Bad, Bid, while anti-apoptotic members include Bcl-2 and Bcl-xL. Post-translational modifications, subcellular localisation and dimerisation are mechanisms by which this large family of proteins regulate apoptosis. 15 Bcr-Abl, but not IL-3 can inhibit the pro-apoptotic activity of overexpressed Bad. To evade apoptotic death induced by overexpressed Bad, Bcr-Abl has been reported to alter the ratio of pro-vs antiapoptotic Bcl-2 family members. 16 The phosphorylation of Bad is important in the anti-apoptotic activity of Bcr-Abl, as Bcr-Abl mutants that fail to phosphorylate Bad are susceptible to apoptosis. 17 The existence of PI3K-dependent, Badindependent signalling pathways downstream of Bcr-Abl involving mitochondrial targeted Raf provide evidence for the redundancy of Bad phosphorylation in Bcr-Abl-mediated survival function. In addition, mitochondrial targeted Raf can phosphorylate Bad and confer a survival signal in haematopoietic cells in the setting of PI3K inhibition. 18 Indeed, PKCdependent activation of Raf is involved in the phosphorylation of Bad. 19 It has been demonstrated that Bcr-Abl can prevent the mitochondrial release of cytochrome c induced by a variety of apoptotic stimuli, however, alterations in the levels of Bcl-2 and Bcl-xL do not appear to be the sole mechanism. 2 A recent study has demonstrated that mitochondrial Bax and cytosolic Apaf-1 levels together are both crucial for the sensitisation of K562 cells to etoposide-induced apoptosis. 20 Pro-apoptotic Bax and Bad are predominantly localised in the cytosol in the absence of an apoptotic signal, and the antiapoptotic Bcl-2 family members are predominantly integral membrane proteins. 21 The pro-apoptotic members are redistributed to the mitochondrion following an apoptotic stimulus. Bax translocation from the cytosol to the mitochondrion and the formation of Bax homodimers occurs following an apoptotic signal. 22, 23 The C-terminus of Bax appears to play an essential role in apoptosis as deletion of this segment abrogates its mitochondrial insertion, 24 and substitution of Bax Cterminus with the Bcl-xL C-terminus abrogates its proapoptotic activity. 25 Indeed, a conformational change in Bax occurs to allow pore formation in cellular membranes. 26 Pro-apoptotic Bad, however, lacks the C-terminus transmembrane domain and is localised in the cytosol, but becomes membrane associated when complexed with Bcl-xL and Bcl-2. The BH3 domain of Bad is required for heterodimerisation with Bcl-xL and Bcl-2 to exert its pro-apoptotic activity. 27 Additionally, Bad is regulated by phosphorylation and activated AKT has been shown to be responsible for Bad phosphorylation on serine 136. 28 The phosphorylation of Bad results in its cytosolic sequestration by 14-3-3 protein. 29 All members of the Bcl-2 family have BH3 domains and thus death promoting activity. Indeed, caspase cleavage of the BH4 domain of Bcl-2 activates the pro-apoptotic activity of the BH3 domain. 30 Therefore, subcellular distribution and the ratio of pro-vs anti-apoptotic Bcl-2 family members localised at the mitochondrion is a critical determinant in the ability of cells to undergo apoptosis.
Currently, there is conflicting evidence regarding the involvement of a decrease in mitochondrial transmembrane potential (⌬ m ) in early apoptotic steps. A reduction in ⌬ m is thought to be mediated by the opening of the mitochondrial transition pore (PTP), and to occur prior to activation of caspases. 31 Bax, Bcl-2 and Bcl-xL can form pH-sensitive, ionconducting channels in planar lipid bilayers, suggesting that they may regulate mitochondrial membrane permeability. Indeed, the addition of Bax to isolated mitochondria results in the permeabilisation of the mitochondrial membrane in the absence of ⌬ m loss. 32, 33 Additionally, caspase inhibitors significantly delayed the decrease in ⌬ m indicating that the release of apoptogenic factors from the mitochondrion can occur in the absence of any detectable decrease in ⌬ m . 34 Thus, caspase activation prior to the loss of ⌬ m supports a model where Bcl-2 family members are involved in mitochondrial membrane permeabilisation. 35 Following the release of apoptotic modulators from the mitochondrion and apoptosome formation (cytochrome c, caspase 9, ATP and Apaf1), procasapse 9 can be activated by oligomerisation and subsequent cleavage. Active caspase 9 can instigate a caspase amplification loop resulting in the activation of other caspases and the execution of the apoptotic pathway.
In a previous study we established that in 32D cells transfected with Bcr-Abl, drug resistance was only achieved in cells expressing high levels of Bcr-Abl. 1 We observed high levels of Bcl-xL and Bax and low levels of Bcl-2 in the absence of a cytotoxic insult in high Bcr-Abl expressing cells. In the present study, we report a novel mechanism whereby Bcr-Abl overexpressing cells may evade apoptotic cell death. High Bcr-Abl expressing cells can block the translocation of Bax and Bad to the mitochondrial membrane following a cytotoxic stimulus. The downstream apoptotic events including caspase 9 and caspase 3 activation, and eventual loss of mitochondrial ⌬ m are blocked. PI3K inhibition does not sensitise drug resistant cells to apoptosis. STAT5 activity appears to be independent of Jak2 activity in high Bcr-Abl expressing cells, however, Jak2 inhibition does not further augment apoptosis in 32D and low Bcr-Abl expressing cells thus questioning a prosurvival role of the Jak/STAT pathway in these cells. This study suggests that the decision to live or die taken by Bcr-Abl cells may be determined by the subcellular distribution of pro-and anti-apoptotic Bcl-2 family members.
Materials and methods

Cell culture/reagents
The 32D cell line was maintained in RPMI 1640, 10% fetal calf serum (FCS), 1% penicillin-streptomycin (P/S) (Gibco BRL, Paisley, UK), and 10% WEHI conditioned media (WEHI-CM) as a source of IL-3. Bcr-Abl transformed 32D cells (32Db2a2), were cloned by serial dilution in media containing 15% FCS and 1.7 g/ml puromycin (Sigma-Aldrich, Dublin, Ireland). Two representative clones expressing low and high levels of Bcr-Abl (C2 and C4, respectively) were selected and chosen for further study. The clones were maintained in RPMI 1640, 10% FCS, 1% P/S and 0.2 g/ml puromycin. Trypan blue exclusion assay was used to determine cell viability and cell number using a Neubauer haemocytometer. AG490 and LY294002 were purchased from Calbiochem (Darmstadt, Germany), etoposide/VP16 from Sigma-Aldrich, UK and IL-3 from Peprotech EC (London, UK).
Assessment of cell death and viability
Cell viability and apoptosis was assessed by propidium iodide (PI) uptake on a FACScan (Becton Dickinson, Oxford, UK) flow cytometer at 590 (FL-2) nm. Cells were incubated with 50 g/ml PI at room temperature (RT) prior to analysis. The criteria for cell death as measured by flow cytometry were based on changes in light scattering properties of dead cells due to cell shrinkage and increased granularity and also permeability to PI. Apoptotic cells were verified using standard morphological criteria following cytospin preparations.
Cell lysis and immunoblotting
Antibodies were as follows: anti c-Abl (ab-3) (Calbiochem), anti-Bax and anti-phospho-STAT5A/B (Upstate Biotechnology, Lake Placid, NY, USA), anti-caspase 3 and anti-caspase 9 (Cell Signaling Technology, Hertfordshire, UK), anti-phosphotyrosine (PY20), anti-Bad, anti-STAT5 and anti-Bcl-xL (Transduction Laboratories, San Diego, CA, USA), anti-AKT and anti-phospho-AKT (ser473) (Cell Signaling Technology, Hertfordshire, UK), and anti-cytochrome oxidase subunit IV (Molecular Probes, Leiden, The Netherlands). Cells were lysed in modified RIPA buffer (50 mM Tris-HCl (pH 7.4), 1% Igepal, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM Na 3 VO 4 , 1 mM NaF, 1 g/ml antipain, 1 g/ml aprotinin, 1 g/ml chymostatin, 0.1 g/ml leupeptin, 1 g/ml pepstatin and 100 M PMSF). Equivalent amounts of protein were resolved using SDS-PAGE and transferred to nitrocellulose membrane (Schleicher and Schuell, Dassel, Germany). All secondary antibodies were peroxidase conjugated and proteins were detected using enhanced chemiluminescence (ECL) (Amersham, Little Chalfont, UK).
For densitometric analysis of the Bcr-Abl/c-Abl ratio, proteins were detected using ECL+Plus (chemifluorescent substrate; Amersham), and scanned using a phosphorimager (Storm 860; Molecular Dynamics, Sunnyvale, CA, USA). Analysis was performed using ImageQuant for Mac (Molecular Dynamics). Density values for actin, c-Abl and Bcr-Abl in 32D, C2 and C4 were obtained and c-Abl and BcrAbl values were normalised to actin. The ratio of Bcr-Abl/cAbl (normalised to actin) was then obtained.
Subcellular fractionation
For separation of cytosolic and mitochondrial fractions, approximately 30-40 million cells were washed twice with ice-cold PBS and resuspended in 200 l of chilled lysis buffer (5 mM Tris pH 7.4, 5 mM KCl, 1.5 mM MgCl 2 , 0.1 mM EGTA pH 8.0, 0.2 mM sodium orthovanadate, 1 mM DTT, 1 g/ml antipain, 1 g/ml aprotinin, 1 g/ml chymostatin, 0.1 g/ml leupeptin, 1 g/ml pepstatin and 100 M PMSF), and incubated on ice for 25 min. The cells were then homogenised with 50 strokes in a 2 ml glass Dounce homogeniser. The homogenate was centrifuged at 700 g for 5 min at 4°C, and the supernatant centrifuged at 10 000 g for 20 min at 4°C, to obtain the mitochondrial pellet. The pellet was washed twice in ice-cold PBS and resuspended in RIPA buffer. The supernatant was centrifuged at 20 000 g for 30 min at 4°C, and the resulting supernatant was termed the cytosolic fraction. Following Biorad protein determination, equal quantities of mitochondrial and cytosolic fractions were resolved using SDS-PAGE, transferred to nitrocellulose membrane and immunoblotted. Mitochondrial and cytosolic fractions were verified using antibodies detecting cytochrome oxidase subunit IV (Cyt.Ox IV) and paxillin, respectively.
Analysis of mitochondrial membrane potential (⌬ m )
Mitochondrial membrane disruption was analysed using JC-1 (Molecular Probes). JC-1 is a dual emission probe with increased fluorescence at 530 nm (FL-1) and reduced fluorescence at 590 nm (FL-2) associated with a decrease in mitochondrial transmembrane potential. Cells were incubated with 5 g/ml JC-1 for 15 min at 37°C and fluorescence measured in both FL-1 and FL-2 channels on a Becton Dickinson FACScan with an excitation of 488 nm.
Assessment of DNA integrity
To examine DNA fragmentation, 5 × 10 5 cells were washed in PBS and resuspended in 20 l DNA extraction buffer (100 mM Tris, 100 mM NaCl, 10 mM EDTA and 1% SDS) and 10 l of 1 mg/ml RNase A (1 mg/ml in 0.1 M sodium acetate, 0.3 mM EDTA pH 4.8) and incubated at 37°C for 30 min. Ten l of 20 mg/ml Proteinase K was then added and incubated at 55°C overnight. Electrophoresis was carried out using 1.5% agarose gels including 0.5 g/ml ethidium bromide and DNA was visualised under UV light.
Results
Caspase activity is blocked in cells expressing high levels of Bcr-Abl
We have previously demonstrated that 32D cells transfected with high levels of the Bcr-Abl onco-protein are resistant to cytotoxic drugs while cells expressing low levels remain drug Leukemia sensitive (Ref. 1 and Figure 1 ). 32D cells are IL-3-dependent, diploid, myeloid progenitor cells. Upon introduction of the Bcr-Abl oncogene, these cells become growth factor independent and are tumorigenic in SCID mice. 36 Here, we were interested in identifying at which step apoptosis was being inhibited in Bcr-Abl expressing cells. Pro-caspase 3 is an executioner caspase that can propagate a caspase cascade involved in apoptosis and is the primary activator of apoptotic DNA fragmentation. Upstream of caspase 3 in the apoptotic pathway lies one of the 'activator caspases', caspase 9. In the presence of etoposide (7.5 g/ml VP16), parental 32D cells and C2 cells (low Bcr-Abl expressors) exhibit a decrease in pro-caspase 3 expression levels and the production of the active 17 kDa subunit (Figure 2a ). To functionally assess active caspase 3, we extracted DNA from treated and untreated cells and analysed the formation of DNA laddering by agarose gel electrophoresis. Figure 2b demonstrates that DNA ladder formation is present only in cells that exhibit active caspase 3. Immunoblot analysis of caspase 9 demonstrates that the pro-caspase 9 levels decrease and the 37 and Analysis of caspase activity in drug-sensitive and drugresistant cells. Indicated cell lines were treated with 7.5 g/ml VP16 for 20 h. (a) Total cell lysates were immunoblotted using anti-Caspase 3 that recognises the 32kDa pro-caspase and 17kDa cleavage product. (b) DNA fragmentation assessed by agarose gel electrophoresis. (c) Total cell lysates were immunoblotted using anti-caspase 9 that recognises the 49 kDa pro-caspase and the 39 and 37 kDa cleavage products.
39 kDa active subunits appear (as a doublet) following incubation with etoposide in the drug sensitive cells (32D and C2) (Figure 2c ). High Bcr-Abl expression (C4 cells) prevents DNA ladder formation and the activation of caspase 3 and caspase 9 (Figure 2a, b, c ). These results demonstrate that the apoptotic pathway is blocked upstream of caspase 9 processing in cells expressing high levels of Bcr-Abl.
High Bcr-Abl expression prevents late mitochondrial depolarisation (⌬ m )
Depolarisation of mitochondria and the subsequent loss of the electrochemical gradient (⌬ m ) across the mitochondrial membrane has been reported to be a key event in apoptotic cell death. We therefore assessed the (⌬ m ) depolarisation using the mitochondrial JC-1 probe following a cytotoxic insult in high and low Bcr-Abl expressing cells. As Figure 3a shows, 32D parental cells and C2 cells exhibit depolarised mitochondria whereas C4 cells did not following treatment with 7.5 g/ml VP16 for 24 h. However, this does not occur at an early stage of the apoptotic process as Figure 3b shows, depolarisation occurs concomitant with cell death assessed by PI uptake. It can be concluded from these results that the apoptotic pathway is blocked at or above the level of the mitochondrion in C4 cells. 
IL-3 co-operates with Bcr-Abl in drug resistance
The 32D cell line is dependent on IL-3 for its survival and proliferation and transfection with the Bcr-Abl oncogene (C2 and C4 cells) renders them IL-3 independent. Although C2 cells do not require IL-3 for their proliferation, they are sensitive to drug-induced apoptosis similar to the parental cells. It has been suggested that the presence of growth factors may participate in delaying apoptotic cell death during the progression of CML 37 and that pathways activated by IL-3 overlap with those activated by Bcr-Abl (ie Jak/STAT and PI3K pathways). Treatment of C2 cells with cytotoxic drugs in the presence and absence of 10% WEHI-CM (as a source of IL-3) was performed to determine if the provision of growth factor to cells expressing low levels of Bcr-Abl could provide an additional anti-apoptotic signal. The percentage of apoptotic cells was significantly reduced (P Ͻ 0.01) when C2 cells were co-incubated with 10% WEHI-CM and VP16 (Figure 4a ). To further investigate the co-operation of IL-3 and Bcr-Abl, we assessed the phospho-tyrosine levels (indicative of tyrosine kinase activity) in 32D, C2 and C4 following incubation with recombinant IL-3. As Figure 4b shows, addition of IL-3 to C2 cells at 0.1 and 1 ng/ml IL-3, increased the phosphotyrosine levels in C2 cells, and this was not seen in 32D cells. This
Figure 4
Overlapping but distinct survival signals provided by IL-3 and Bcr-Abl. (a) C2 cells were treated with VP16 in the presence/absence of 10% WEHI-CM. At 24 h, % cell death was determined by PI uptake on a FACSan and graphically presented by the mean of three individual experiments. Statistical analysis was performed using an unpaired Student's t-test (*P Ͻ 0.01). (b) Total cell lysates from 32D, C2 and C4 cells treated with the indicated ng/ml concentrations of recombinant IL-3 (rIL-3) for 24 h, were immunoblotted using an anti-phosphotyrosine (PY20) antibody.
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indicates that indeed IL-3 can co-operate with Bcr-Abl in promoting survival in C2 cells.
Inhibition of Jak2 does not alter drug sensitivity
Jak2 tyrosine phosphorylation is regulated by IL-3, which can lead to STAT5 activation, and the Jak2/STAT5 pathway has been associated with leukaemic cell survival. 38 AG490 has been shown to inhibit the tyrosine phosphorylation of Jak2 and leukaemic cell growth with no cytotoxic effects to normal haematopoiesis at concentrations up to 50 M. 39 Figure 5a demonstrates that 50 M AG490 can inhibit STAT5 activity (as assessed by anti-phospho-STAT5 immunoblot) in IL-3 stimulated 32D cells and low Bcr-Abl expressing cells (C2 cells) indicating that STAT5 activity is dependent on Jak2 activity. However, STAT5 activity was not suppressed in high Bcr-Abl expressing cells (C4) in the presence of 50 M AG490. Therefore, in high Bcr-Abl expressing cells, STAT5 activity appears to be independent of Jak2 activity. Despite the inhibition of STAT5 activity in 32D and C2 cells, coincubation with VP16 did not further increase the sensitivity of these cells to apoptosis (Figure 5b and c) .
Inhibition of PI3K does not alter drug sensitivity
Previous reports have shown that the PI3K/AKT pathway can protect cells from growth factor withdrawal-induced apoptosis 40 and that Bcr-Abl activates this pathway to protect against apoptosis. Therefore, we assessed the contribution of this pathway in drug-sensitive and drug-resistant cells. Figure  6a shows that in the presence of 20 M LY294002, AKT phosphorylation (ser473) was completely blocked in 32D, C2 and C4 cells demonstrating the inhibition of PI3K activity. To ascertain if this pathway was involved in the protection from apoptosis, 32D, C2 and C4 cells were incubated in the presence and absence of 7.5 g/ml VP16 and 20 M LY294002. As shown in Figure 6b , inhibition of the PI3K pathway does not sensitise C4 cells to drug-induced apoptosis, or further increase the susceptibility of 32D and C2 cells to apoptosis.
Translocation of Bax to the mitochondria is blocked in cells expressing high levels of Bcr-Abl
We have previously reported that the drug-resistant C4 cells express elevated Bax and downregulate Bcl-2. As this is usually associated with drug sensitivity we investigated the subcellular distribution of Bcl-2 members. We performed cytosolic and mitochondrial extractions from 32D, C2 and C4 cells following 4 and 8 h incubations with VP16. In untreated 32D and C2 cells (Figure 7a and b) , Bax is localised predominantly in the cytosol. However, following a 4-h treatment with 7.5 g/ml VP16, Bax redistributes to the mitochondrion in response to the apoptotic stimulus. Bcl-xL is located primarily in the mitochondrial fraction and does not redistribute following VP16 treatment.
Despite C4 cells expressing high levels of Bax, it is localised mainly in the cytosol of untreated samples (Figure 7c ) negating its pro-apoptotic properties. Bcl-xL expression is elevated; it is located in the mitochondrial fraction and to a lower extent, in the cytosolic fraction of untreated C4 cells. Following an apoptotic stimulus, the subcellular distribution of Bax and BclxL in C4 cells did not change. These results indicate that Bax translocation from the cytosol to the mitochondrion may be a key feature in the apoptotic pathway in 32D cells and C2 cells, possibly by its homodimerisation and facilitation of the release of mitochondrial apoptogenic factors. No subcellular redistribution of Bax occurs in C4 cells subsequent to an apoptotic stimulus, suggesting that translocation of Bax may be a critical event in apoptosis in 32D and C2 cells.
Bad translocation to the mitochondria does not occur in high Bcr-Abl expressing cells
Another pro-apoptotic member of the Bcl-2 family, Bad, plays an important role in the regulation of apoptotic vs survival signals. Bad can heterodimerise with Bcl-xL to sequester it away from Bax, allowing Bax to carry out its pro-apoptotic function at the mitochondria. Therefore, we assessed the Bax and Bcl-xL subcellular distribution and translocation in response to VP16. Cytoplasmic and mitochondrial preparations from untreated and VP16-treated (a) 32D, (b) C2 and (c) C4 cells at the indicated time points. Equal proportions of the cytoplasmic and mitochondrial preparations were analysed by Western blotting for the localisation of Bax and Bcl-xL. Immunoblots for cytochrome C oxidase subunit IV (Cyt.ox.IV) are shown as markers for mitochondrial preparations.
expression and subcellular distribution of Bad in untreated and VP16-treated 32D, C2 and C4 cells. Bad is expressed at a much higher level in C4 drug-resistant cells (Figure 8a ) compared to 32D and C2 cells. We then performed cytosolic and mitochondrial extractions to assess the subcellular distribution of Bad (Figure 8b) . Bad was located exclusively in the cytosolic fraction of untreated C4 cells. In 32D and C2 untreated cells, Bad was distributed mainly in the cytosol, with some localised to mitochondria. However, when 32D and C2 cells were treated with VP16, there was an increase in the level of Bad localised at the mitochondrion. This translocation of Bad did not occur in VP16-treated C4 cells. These results indicate that C4 cells can evade apoptotic cell death by preventing alteration in the subcellular distribution of Bax and Bad, and ultimately preventing key mitochondrial apoptotic events.
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Figure 8
Bad expression, subcellular distribution and translocation in response to VP16. (a) 32D, C2 and C4 total cell lysates were immunoblotted using anti-Bad. (b) Equal proportions of cytoplasmic and mitochondrial fractions from untreated and VP16 treated 32D, C2 and C4 were immunoblotted using anti-Bad.
Discussion
We have previously provided evidence for the requirement of high Bcr-Abl levels to abrogate drug-induced apoptosis, as cells expressing low Bcr-Abl levels are drug sensitive, and cells expressing high Bcr-Abl levels are drug resistant. 1 Here, we further investigated the mechanisms by which this drug resistance may be achieved. In high Bcr-Abl expressing cells (C4), key apoptotic events such as caspase activation and mitochondrial depolarisation do not occur in response to cytotoxic drugs indicating that apoptosis is inhibited either at or above the level of the mitochondrion. We therefore further investigated the role of specific signal transduction pathways which have been previously associated with apoptosis resistance, and examined the role of the Bcl-2 family of apoptosis regulators.
In the 32D cell line, moderate expression of Bcr-Abl renders the cells IL-3 independent but drug sensitive. However, the further addition of IL-3 to low expressing C2 cells can cooperate with Bcr-Abl to significantly reduce apoptotic cell death induced by a cytotoxin. Indeed phospho-tyrosine levels could be increased in C2 cells but not in 32D cells with further addition of IL-3, suggesting some synergy between BcrAbl and IL-3 pathways. We therefore investigated the contribution of two signalling pathways utilised by IL-3, (Jak/STAT; PI3K/AKT) to drug sensitivity/resistance in our cell lines.
We have previously reported increased Bcl-xL expression in Bcr-Abl-positive 32D cells. The fractionation/extraction method employed in this paper further indicates higher levels of Bcl-xL in the C4 (high Bcr-Abl) cell line. Transcription of Bcl-xL by Bcr-Abl via STAT5 has been documented. 11 In order to determine the role of Jak2/STAT5 in 32D Bcr-Abl cells, we employed AG490, a specific inhibitor of Jak2. 39 A previous study has demonstrated that when growth factor dependence was restored to Bcr-Abl expressing cells by treatment with STI571 (a specific Bcr-Abl inhibitor) synergy between AG490 and STI571 occurred. 41 However, in this study inhibition of the Jak2/STAT5 pathway with 50 M AG490 could not further sensitise 32D cells or low Bcr-Abl expressors (C2 cells) to apoptosis.
Other studies have shown that in haematopoietic cells stimulated by IL-3, Bad is phosphorylated and sequestered in the cytosol by 14-3-3 proteins, prohibiting its inhibition of Bcl-xL. 29 The signal from the IL-3 receptor to Bad occurs via AKT and PI3K, and it has been reported that the PI3K/AKT pathway is essential for leukaemogenesis. 12 However, in this study, inhibition of the PI3K pathway with LY294002 could not sensitise C4 drug-resistant cells to apoptosis. Other studies have also reported that Bcr-Abl-mediated resistance to druginduced apoptosis was independent of PI3K activity, 42 and a dominant negative PI3K regulatory subunit could not prevent the anti-apoptotic signal emanating from IL-3. 43 These data show that for low Bcr-Abl expressing cells IL-3 can provide an additional survival signal. However, we could not influence susceptibility to drug-induced apoptosis by independent inhibition of Jak2 and PI3Kpathways. It is possible that a combination of various signalling pathways is important to influence susceptibility to apoptosis. Other studies focusing on the molecular perturbations that contribute to apoptosis resistance in Bcr-Abl expressing cells have also suggested that multiple survival pathways may be involved. 16, 18 We have also demonstrated that STAT5 activity could not be suppressed using 50 M AG490 in high Bcr-Abl expressors, a concentration that can inhibit STAT5 activity in 32D cells and low Bcr-Abl expressors (C2 cells). These data are in agreement with studies reporting that Bcr-Abl may bypass the requirement for Jak2 in the activation of STAT5. 44 The Jak2-independent phosphorylation of STAT5 further confirms that when Bcr-Abl expression is elevated, new targets can be modified, thereby influencing the phenotype of the cell. It remains possible that the activated STAT5 is responsible for the slightly elevated expression of Bcl-xL in C4 cells and that this may contribute to their drug resistance. However, other studies have compared apoptosis resistance imparted by Bcl-xL and Bcr-Abl and indicated that Bcr-Abl has a much stronger anti-apoptotic effect. 2, 3 We therefore further investigated the role of pro-apoptotic mediators in the Bcr-Abl expressing cells. Knockout studies also indicate the importance of pro-apoptotic members, Bax or Bak, in order to respond to diverse apoptotic stimuli. 45 Bcl-2 family members may be regulated by transcription, post-translational modifications, dimerisation and subcellular distribution. Bad can heterodimerise with Bcl-xL and Bcl-2, dampening their anti-apoptotic functions and Bax can then homodimerise to promote apoptosis. 46 In healthy cells, Bax is located in the cytosol and following an apoptotic stimulus is inserted into the mitochondrial membrane. 24 The C-terminus plays a key role in determining Bax subcellular localisation and the insertion into the mitochondrial membrane (poreforming) is essential for pro-apoptotic activity. 47 Bax functionally interacts with channel proteins resident in mitochondrial membranes, such as VDAC, ANT, and the FoF1 ATPase proton pump in both mammalian and yeast cells. 31 In our study we have shown that Bax and Bad translocated to the mitochondrion in drug-sensitive cells, but not in the drugresistant cells that overexpressed them. The lack of Bax and Bad translocation in high Bcr-Abl expressing cells described here suggests that the sequestration of Bax and Bad in the cytosol may be mediated by post-translational mechanisms that are influenced by Bcr-Abl. It is also possible that the high endogenous levels of Bcl-xL at the mitochondrion in C4 cells may prevent Bax dimerisation and insertion into the mitochondrial membrane. Other studies have demonstrated that translocation and dimerisation of Bax can be reduced by the overexpression of Bcl-xL and Bcl-2. 22, 48 The localisation of Bad is known to be important in apoptosis induced by IL-3 withdrawal. When it is in the unphosphorylated form, it binds to and sequesters mitochondrial Bcl-xL, promoting apoptosis. Bad translocation from the cytosol to the mitochondrion occurs following a cytotoxic stimulus in 32D and C2 cells. However, in C4 cells the antiapoptotic activity of mitochondrial Bcl-xL is likely to be further potentiated by the inability of Bad to relocalise and heterodimerise with it. The inhibitor LY294002 interferes with the activity of PI3K thereby blocking the phosphorylation of Bad on serine 136 by AKT. The inability of LY294002 to synergise with VP16 to induce apoptosis does not rule out the phosphorylation and cytosolic sequestration of Bad by other kinases. Indeed, additional kinases are emerging that can phosphorylate Bad, for example, PKA which phosphorylates Bad on serine 112 and serine 155. 49 An increased expression level of Bad has also been reported in other Bcr-Abl-positive cells. 18 This, together with the data presented here, implies that the magnitude of the Bcr-Abl signal in C4 cells is able to efficiently inactivate a greater pool of Bad, by preventing its translocation.
In conclusion, this study has shown that the achievement of drug resistance by Bcr-Abl is associated with the prevention of Bax and Bad translocation from the cytosol to the mitochondrion following an apoptotic stimulus. The mechanism by which this is achieved is unknown, but it may require the influence of multiple survival pathways acting on individual Bcl-2 family members, as independent inhibition of PI3K does not sensitise drug resistant cells to apoptosis, and inhibition of Jak2/STAT5 pathway could not further sensitise 32D and C2 cells to drug-induced apoptosis. The inability of key proapoptotic proteins to locate at their site of functional activity could play a major role in resistance to drug-induced apoptosis in high Bcr-Abl expressing cells.
